A prospective, randomized study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan 200 mg/m2 (MEL200) in newly diagnosed myeloma patients: an interim analysis  »    PDF - 355 KB

Antonio Palumbo¹, Federica Cavallo², Dina Ben Yehuda², Paola Omede², Agostina Siniscalchi², Maide Cavalli², Barbara Lupo², Aaron Polliack², Izhar Hardan², Fabiana Gentilini², Paolo Corradini², Claudia Crippa², Fausto Rossini², Francesca Patriarca², Annalisa Citro², Alessandro Petrucci², Angelo Michele Carella², Giulia Benevolo², Tommaso Caravita², Francesco Di Raimondo², Mario Boccadoro²
1. Division of Hematology, University of Torino, Torino, Italy, EU
2. European Myeloma Network, EU

Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) followed by maintenance with Bortezomib and Thalidomide (VT) for initial treatment of elderly multiple myeloma patients  »    PDF - 402 KB

A. Palumbo¹, S. Bringhen¹, D. Rossi², R. Ria², M. Offidani², F. Patriarca², C. Nozzoli², A. Levi², T. Guglielmelli², G. Benevolo², V. Callea², B. Olivero², F. Morabito², M. Grasso², R. Marasca², M. Rizzo², A. Falcone², D. Gottardi², V. Montefusco², C. Musolino², R. Zambello², C. Cangialosi², G. Pietrantuono², V. Magarotto¹, M.T. Petrucci², P. Musto², G. Ciccone², F. Di Raimondo², G. Gaidano², M. Boccadoro¹
1. Division of Hematology, University of Torino, Torino, Italy, EU
2. Italian Multiple Myeloma Network, GIMEMA, Italy

Phase 3b UPFRONT Study: Interim Results from a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients  »    PDF - 92 KB

Ruben Niesvizky¹, James Reeves², Ian Flinn³, Robert Rifkin⁴, Billy Clowney⁵, Nashat Gabrail⁶, Vijay Phooshkooru⁷, Veena Charu⁸, Christopher Chay⁹, Deyanira Corzo¹⁰, Rachel Neuwirth¹⁰, Robert Manges¹¹, Thomas Warr¹², on behalf of the UPFRONT Study Group
1. Center of Excellence for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, NY
2. Florida Cancer Specialists, Bonita Springs, FL
3. Sarah Cannon Research Institute, Nashville, TN
4. Rocky Mountain Cancer Centers, US Oncology, Denver, CO
5. Santee Hematology/Oncology, Sumter, SC
6. Gabrail Cancer Center, Canton, OH
7. Mid Dakota Clinic, Bismarck, ND
8. Pacific Cancer Medical Center, Anaheim, CA
9. Cancer Care of WNC, Asheville, NC
10. Millennium Pharmaceuticals, Inc., Cambridge, MA
11. Investigative Clinical Research of Indiana, Indianapolis, IN
12. Clinic Cancer Care, Great Falls, MT

A Phase 1b Multicenter Dose Escalation Study of Carfilzomib plus Lenalidomide and Low-dose Dexamethasone in Relapsed Multiple Myeloma  »    PDF - 409 KB

R. Niesvizky¹, M. Wang², W. Bensinger³, M. Alsina⁴, N Gabrail⁵, M. Vallone⁶, A.A. Gutierrez⁶, M. Kauffman⁶
1. Weill Cornell Medical College, New York, NY
2. MD Anderson Cancer Center, Houston, TX
3. Fred Hutchinson Cancer Research Center, Seattle, WA
4. H. Lee Moffitt Cancer Center & Research Center, Tampa, FL
5. Gabrail Cancer Center, Canton, OH
6. Onyx Pharmaceuticals, Inc., Emeryville, CA

A Phase 3 Historically-Controlled Clinical Trial Investigating the Use of Defibrotide (DF) in the Treatment of Severe Veno-Occlusive Disease Following SCT  »    PDF - 203 KB

P G Richardson, MD¹, M Tomblyn, MD², N Kernan, MD³, J Brochstein, MD⁴, S Mineishi, MD⁵, A Termuhlen, MD⁶, S Arai, MD⁷, S Grupp MD⁸, E Guinan, MD¹, P Martin, MD⁹, S Corbacioglu MD¹⁰, E Holler MD¹¹, R D'Agostino, PhD¹², J Massaro PhD¹², A Hannah, MD¹³, M Iacobelli, MD¹³, R Soiffer, MD¹
1. Dana-Farber Cancer Ctr, Mass General, Children's Hosp, Boston, MA
2. Univ Minnesota Cancer Ctr, Minneapolis, MN
3. Memorial Sloan-Kettering Cancer Ctr, New York, NY
4. Hackensack Univ Med Ctr, Hackensack, NJ
5. Univ Michigan, Ann Arbor MI
6. Nationwide Children’s Hospital
7. Stanford Univ Med Ctr, Stanford, CA
8. Children’s Hosp of Philadelphia, Philadelphia PA
9. Duke Univ Med Ctr, Durham, NC
10. Univ Ulm, Ulm, Germany
11. Klinikum der Univ Regensburg, Regensburg, Germany
12. Boston Univ, Boston, MA
13. Gentium,SpA, Villa Guardia, Como, Italy

Changes in serum free light chain rather than intact monoclonal immunoglobulin levels predict outcome with therapy in patients with light chain amyloidosis  »    PDF - 792 KB

Shaji Kumar, Morie Gertz, Martha Lacy, Suzanne Hayman, Francis Buadi, Steven Zeldenrust, Marina Ramirez-Alvarado, Nelson Leung, Angela Dispenzieri
Mayo Clinic

Time Trends in Allogeneic Stem Cell Transplantation for Multiple Myeloma: A CIBMTR Analysis  »    PDF - 157 KB

Shaji Kumar, MD*
Mayo Clinic, Rochester, MN
*On behalf of the Plasma Cell Disorders Working Committee,
Center for International Blood and Marrow Transplant Research

Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse vs. Early Transplantation  »    PDF - 1,69 MB

Shaji Kumar, Martha Q. Lacy, Angela Dispenzieri, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Francesca Gay, William Hogan, S. Vincent Rajkumar, Morie A Gertz
Mayo Clinic

How to treat a newly diagnosed young patient with multiple myeloma  »    PDF - 474 KB

J.F. San Miguel
University of Salamanca, Spain

Novel Three- and Four-Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Results from the Multi-Center, Randomized, Phase 2 EVOLUTION Study  »    PDF - 141 KB

Shaji Kumar¹, Ian Flinn², Parameswaran Hari³, Natalie Callander⁴, Stephen J Noga⁵, A Keith Stewart⁶, Jonathan Glass⁷, Noopur Raje⁸, Robert Rifkin⁹, Hongliang Shi¹⁰, Iain J Webb¹⁰, Paul G Richardson¹¹, S Vincent Rajkumar¹
1. Division of Hematology, Mayo Clinic, Rochester, MN
2. Sarah Cannon Research Institute, Nashville, TN
3. Medical College of Wisconsin, Milwaukee, WI
4. University of Wisconsin Comprehensive Cancer Center, Madison, WI
5. Sinai Hospital of Baltimore, Baltimore, MD
6. Mayo Clinic Arizona, Scottsdale, AZ
7. Louisiana State University Health Sciences Center, Shreveport, LA
8. Massachusetts General Hospital, Boston, MA
9. Rocky Mountain Cancer Centers, Denver, CO
10. Millennium Pharmaceuticals, Inc., Cambridge, MA
11. Dana-Farber Cancer Institute, Boston, MA

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Pts With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib; Preliminary Results  »    PDF - 139 KB

Paul Richardson¹, David Siegel², Rachid Baz³, Susan L Kelley⁴, Nikhil C Munshi¹, Daniel Sullivan³, Laura McBride², Deborah Doss¹, Gail Larkins⁵, Christian Jacques⁵, Arlene Donaldson⁵, Kenneth C Anderson¹
1. Dana-Farber Cancer Institute, Boston, MA
2. Hackensack University Medical Center, Hackensack, NJ
3. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
4. Multiple Myeloma Research Consortium, Norwalk, CT
5. Celgene Corporation, Summit, NJ